https://scholars.lib.ntu.edu.tw/handle/123456789/568804
標題: | Efficacy of consensus interferon in the treatment of chronic hepatitis C | 作者: | JIA-HORNG KAO PEI-JER CHEN Lai M.-Y. DING-SHINN CHEN |
公開日期: | 2000 | 出版社: | Blackwell Publishing | 卷: | 15 | 期: | 12 | 起(迄)頁: | 1418-1423 | 來源出版物: | Journal of Gastroenterology and Hepatology (Australia) | 摘要: | Background and Aims: Consensus interferon (CIFN) is a newly developed type I interferon. The aim of this study was to investigate the safety and efficacy of CIFN in the treatment of patients with chronic hepatitis C and to determine the predictors for sustained response. Methods: Patients were randomized to receive 3 μg or 9 μg CIFN three times a week for 24 weeks, followed by 24 weeks of observation. Efficacy was assessed by normalization of serum transaminase levels and disappearance of serum hepatitis C virus (HCV)-RNA at the end of treatment and at 24 weeks after stopping treatment. Histologic response was defined as a decrease of at least two points in the Knodell necroinflammatory score at week 48 and was compared with baseline. Results: There were no serious adverse effects related to CIFN therapy. Overall, 44% of patients receiving 3 μg and 48% of patients receiving 9 μg had normalization of serum transaminase levels and disappearance of HCV viremia at the end of treatment. At 24 weeks after stopping treatment, 16% of patients in receiving 9 μg and 12% of patients receiving 3 μg had sustained responses. The histologic responses in patients receiving 9 μg and those receiving 3 μg were 60% and 36%, respectively. The necroinflammatory score was significantly reduced from baseline to week 48 in both groups. In addition, bodyweight < 60 kg and pretreatment serum HCV-RNA level < 0.5 MEq/mL can serve as predictors for sustained response to CIFN treatment. Conclusions: These findings suggest that 9 μg CIFN is safe and effective in the treatment of patients with chronic hepatitis C. ? 2000 Blackwell Science Asia Pty Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984559279&doi=10.1046%2fj.1440-1746.2000.02371.x&partnerID=40&md5=e8e288e49114439b5344971a49cfe21e https://scholars.lib.ntu.edu.tw/handle/123456789/568804 |
ISSN: | 0815-9319 | DOI: | 10.1046/j.1440-1746.2000.02371.x | SDG/關鍵字: | aminotransferase; consensus interferon; virus RNA; adult; aminotransferase blood level; arthralgia; article; body weight; chronic hepatitis; clinical article; clinical trial; controlled clinical trial; controlled study; dose response; drug efficacy; drug safety; drug tolerability; fatigue; female; hepatitis C; Hepatitis C virus; human; human tissue; male; priority journal; randomized controlled trial; scoring system; viremia |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。